Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MITF | O75030 | 3/20 | 0.63 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 5/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.56 |
| ▸ | RORC | P51449 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | XBP1 | P17861 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7735911 | 0.84 | MITF (0.63) | MITFKLF5ALDH1A1HPGDNPC1 | |
| SCHEMBL517540 | 0.84 | MITF (0.63) | MITFKLF5ALDH1A1HPGDNPC1 | |
| SCHEMBL6688374 | 0.82 | HDAC3 (0.51) | MITFKLF5ALDH1A1HPGDNPC1 | |
| SCHEMBL11356835 | 0.81 | HDAC8 (0.64) | MITFKLF5ALDH1A1HPGDNPC1 | |
| SCHEMBL11215485 | 0.80 | HDAC8 (0.62) | MITFKLF5ALDH1A1HPGDNPC1 | |
| SCHEMBL7738147 | 0.79 | ALDH1A1 (0.81) | MITFKLF5ALDH1A1HPGDNPC1 | |
| SCHEMBL7940080 | 0.79 | MITF (0.58) | MITFKLF5ALDH1A1HPGDNPC1 | |
| SCHEMBL9081388 | 0.78 | NPC1 (0.76) | MITFALDH1A1HPGDNPC1SMN1; SMN2 | |
| SCHEMBL22291721 | 0.78 | HTR2C (0.58) | MITFKLF5HPGDNPC1HDAC8 | |
| SCHEMBL22291719 | 0.78 | HTR2C (0.58) | MITFKLF5HPGDNPC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567477-B1 | SUBSTITUTED AMINO PHENYLACETIC ACIDS, DERIVATIVES THEREOF, THEIR PREPARATION AND THEIR USE AS CYCLOOXYGENASE 2 (COX-2) INHIBITORS | NOVARTIS AG (CH) | 2009-09-09 | — | — | EP | disclosed |
| EP-2090566-A2 | Certain phenylacetic acids and derivatives | Novartis AG (CH) | 2009-08-19 | — | — | EP | disclosed |
| US-7202364-B2 | Certain phenylacetic acids and derivatives | NOVARTIS, AG (CH) | 2007-04-10 | — | — | US | disclosed |
| CN-1729157-A | Substituted amino phenylacetic acids, derivatives thereof, their preparation and their use as cyclooxygenase 2 (COX-2) inhibitors | NOVARTIS AG (CH) | 2006-02-01 | — | — | CN | disclosed |
| EP-1567477-A1 | SUBSTITUTED AMINO PHENYLACETIC ACIDS, DERIVATIVES THEREOF, THEIR PREPARATION AND THEIR USE AS CYCLOOXYGENASE 2 (COX-2) INHIBITORS | Novartis AG (CH) | 2005-08-31 | — | — | EP | disclosed |
| US-20040132769-A1 | Certain phenylacetic acids and derivatives | NOVARTIS AG (CH) | 2004-07-08 | — | — | US | disclosed |
| WO-2004048314-A1 | SUBSTITUTED AMINO PHENYLACETIC ACIDS, DERIVATIVES THEREOF, THEIR PREPARATION AND THEIR USE AS CYCLOOXYGENASE 2 (COX-2) INHIBITORS | NOVARTIS AG (CH) | 2004-06-10 | — | — | WO | disclosed |
| US-6410792-B1 | OBESITY DISEASES | BAYER CORPORATION | 2002-06-25 | — | — | US | disclosed |
| US-6048900-A | FOR TREATING EATING DISORDERS, INSULIN RESISTANT DIABETES, HYPERTENSION, HYPERLIPEMIA | BAYER CORPORATION (US) | 2000-04-11 | — | — | US | disclosed |
| EP-0910565-A1 | AMIDE DERIVATIVES AS SELECTIVE NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | Bayer Corporation (US) | 1999-04-28 | — | — | EP | disclosed |
| WO-1998035957-A1 | AMIDE DERIVATIVES AS SELECTIVE NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | BAYER CORPORATION (US) | 1998-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132769-A1 | Certain phenylacetic acids and derivatives | CYP2A6, HCAR2, CYP2B6 | MITF 2553/4885KLF5 3978/4885ALDH1A1 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.